

Research article

Open Access

Conjugated docosahexaenoic acid suppresses KPL-1 human breast cancer cell growth *in vitro* and *in vivo*: potential mechanisms of action

Miki Tsujita-Kyutoku^{1,2}, Takashi Yuri¹, Naoyuki Danbara¹, Hideto Senzaki¹, Yasuhiko Kiyozuka¹, Norihisa Uehara¹, Hideho Takada³, Takahiko Hada⁴, Teruo Miyazawa⁵, Yutaka Ogawa² and Airo Tsubura¹

¹Department of Pathology II, Kansai Medical University, Moriguchi, Osaka, Japan

²Department of Plastic and Reconstructive Surgery, Kansai Medical University, Moriguchi, Osaka, Japan

³Division of Surgery, Kansai Medical University Kori Hospital, Neyagawa, Osaka, Japan

⁴R&D Division, Bizen Chemical Co., Ltd, Okayama, Japan

⁵Laboratory of Biodynamic Chemistry, Tohoku University Graduate School of Life Science and Agriculture, Sendai, Japan

Corresponding author: Airo Tsubura, tsubura@takii.kmu.ac.jp

Received: 17 Dec 2003 Revisions requested: 30 Jan 2004 Revisions received: 10 Mar 2004 Accepted: 12 Mar 2004 Published: 26 Apr 2004

Breast Cancer Res 2004, **6**:R291-R299 (DOI 10.1186/bcr789)

© 2004 Tsujita-Kyutoku *et al.*; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL

Abstract

Introduction The present study was conducted to examine the effect of conjugated docosahexaenoic acid (CDHA) on cell growth, cell cycle progression, mode of cell death, and expression of cell cycle regulatory and/or apoptosis-related proteins in KPL-1 human breast cancer cell line. This effect of CDHA was compared with that of docosahexaenoic acid (DHA).

Methods KPL-1 cell growth was assessed by colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay; cell cycle progression and mode of cell death were examined by flow cytometry; and levels of expression of p53, p21^{Cip1/Waf1}, cyclin D₁, Bax, and Bcl-2 proteins were examined by Western blotting analysis. *In vivo* tumor growth was examined by injecting KPL-1 cells subcutaneously into the area of the right thoracic mammary fat pad of female athymic mice fed a CDHA diet.

Results CDHA inhibited KPL-1 cells more effectively than did DHA (50% inhibitory concentration for 72 hours: 97 μmol/l and

270 μmol/l, respectively). With both CDHA and DHA growth inhibition was due to apoptosis, as indicated by the appearance of a sub-G₁ fraction. The apoptosis cascade involved downregulation of Bcl-2 protein; Bax expression was unchanged. Cell cycle progression was due to G₀/G₁ arrest, which involved increased expression of p53 and p21^{Cip1/Waf1}, and decreased expression of cyclin D₁. CDHA modulated cell cycle regulatory proteins and apoptosis-related proteins in a manner similar to that of parent DHA. In the athymic mouse system 1.0% dietary CDHA, but not 0.2%, significantly suppressed growth of KPL-1 tumor cells; CDHA tended to decrease regional lymph node metastasis in a dose dependent manner.

Conclusion CDHA inhibited growth of KPL-1 human breast cancer cells *in vitro* more effectively than did DHA. The mechanisms of action involved modulation of apoptosis cascade and cell cycle progression. Dietary CDHA at 1.0% suppressed KPL-1 cell growth in the athymic mouse system.

Keywords: apoptosis, breast cancer, conjugated docosahexaenoic acid, docosahexaenoic acid, human

Introduction

The etiology of human breast cancer is complex and remains poorly understood. At least one-third of all human cancers may be associated with dietary factors [1]. In particular, it has been hypothesized that dietary fat intake plays a role in the development and progression of breast cancer.

Evidence from very large prospective studies strongly suggests that there is no association between overall dietary fat intake and breast cancer in humans [2]. However, such findings do not necessarily mean that fat has no effect on breast cancer, because other findings indicate that the type of dietary fat consumed is of particular importance in breast

CDHA = conjugated docosahexaenoic acid; CLA = conjugated linoleic acid; DHA = docosahexaenoic acid; DMEM = Dulbecco's modified Eagle's minimum essential medium; FBS = fetal bovine serum; IC₅₀ = 50% inhibitory concentration; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PBS = phosphate-buffered saline; PUFA = polyunsaturated fatty acid.

carcinogenesis [3]. Epidemiologic data in Alaskan and Greenland Eskimos [4,5] and in non-Eskimo populations [6] indicate that consumption of fish oil correlates with reduced incidence of breast cancer. In experimental studies using human breast cancer cells [7,8] eicosapentaenoic acid and docosahexaenoic acid (DHA) – n-3 polyunsaturated fatty acids (PUFAs) that are abundant in fish oil – have exhibited protective effects. Perilla oil, which contains a high level of α -linolenic acid (an n-3 PUFA), similarly inhibits mammary carcinogenesis in rats [9,10]. Thus, n-3 PUFAs appear to be of particular importance in suppression of breast carcinogenesis.

Conjugated fatty acids are positional and geometrical isomers with conjugated double bonds. Conjugated linoleic acid (CLA) is found in meat from ruminants and in dairy products [11], and has been shown to have anticarcinogenic effects [12-14]. It has been reported that CLA reduces mammary cancer risk in rats [15-17] and inhibits growth of human breast cancer cells in culture [18]. Linoleic acid, an n-6 PUFA, accelerates growth of human breast cancer cells [8]. Thus, the finding that CLA has the opposite effect is of particular interest. Given that n-3 PUFAs have been shown to have anticarcinogenic activity *in vitro* and *in vivo*, some conjugated fatty acids converted from n-3 PUFAs may have greater tumor suppressing activity than CLA or n-3 PUFAs themselves. We recently showed that DHA, an n-3 PUFA, suppresses mammary cancer in rats more effectively than does eicosapentaenoic acid [19]. Conjugated eicosapentaenoic acid is naturally found in seaweeds [20]. Conjugated DHA (CDHA) is not found naturally and is artificially prepared by alkaline isomerization of DHA [21]. In the present study, the tumor-suppressing effect of CDHA was examined *in vitro* and *in vivo*, and its anticarcinogenic activity was compared with that of DHA. Also, the mechanisms by which CDHA suppresses cancer cell growth were investigated.

Methods

Human breast cancer cell line and culture conditions

KPL-1 is a human breast carcinoma cell line that was established from the malignant effusion of a breast cancer patient [22]. This cell line is estrogen receptor positive, grows rapidly in female athymic mice, and often causes regional lymph node metastasis when inoculated into the mammary fat pad. KPL-1 cells were maintained in Dulbecco's modified Eagle's minimum essential medium (DMEM 0/5921; Sigma, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; Gibco BRL, Grand Island, NY, USA), and were grown at 37°C in 5% carbon dioxide/95% humidified air.

DHA and preparation of CDHA by alkaline treatment

DHA ethyl ester (purity 97%) was obtained from Bizen Chemical (Okayama, Japan). CDHA was prepared by alka-

line treatment [21]. Briefly, a solution of potassium hydroxide in ethylene glycol was prepared at a concentration of 21% (weight:weight), and this solution was bubbled with nitrogen gas. Then, 100 g DHA ethyl ester was added to 1000 ml of the 21% potassium hydroxide/ethylene glycol solution. The mixture was bubbled with nitrogen gas and allowed to stand for 10 min at 180°C. The reaction mixture was cooled and 1000 ml methanol was added. The mixture was acidified with 2000 ml of 6 N HCl. After dilution with 2000 ml distilled water, the conjugated fatty acid was extracted with 5000 ml n-hexane. The hexane extract was then washed with 3000 ml of 30% methanol/distilled water, washed with 3000 ml distilled water, and finally evaporated under the nitrogen gas stream to produce CDHA. DHA isomerized with 21% potassium hydroxide for 10 min preferentially forms conjugated pentaene and conjugated hexaene [21]. The purity of CDHA used in the following experiments was approximately 65% (35% was unreacted and remained as DHA). DHA and CDHA were stored at -80°C in the dark.

MTT assay

Viable cells exposed to DHA or CDHA were quantified using a colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.

Stock solutions of DHA or CDHA in ethanol were prepared at a concentration of 500 mmol/l. For each experiment test compound was prepared from the stock solution and diluted to a final concentration of 1 μ mol/l to 5×10^2 μ mol/l with culture medium. Initially, 5×10^3 KPL-1 cells were seeded in 96-well culture plates and cultured for 24 hours to allow them to adhere to the plates. After preincubation, the culture medium was changed to the experimental medium supplemented with DHA or CDHA. We used four concentrations of each test compound, covering a 3-log range (1 μ mol/l to 5×10^2 μ mol/l) that was chosen to span the 50% inhibitory concentration (IC_{50}) determined in preliminary assays. The final concentration of ethanol never exceeded 0.2% (vol:vol). Control cells were exposed to test medium supplemented with 0.2% ethanol. After incubation with the test compound for 24, 48 or 72 hours, MTT (Sigma) was added and the plate samples were then read in eight wells at an optical density value of 540 nm. Untreated controls were incubated with culture medium alone. The percentages of surviving cells, as compared with untreated controls, were calculated.

Flow cytometry

To evaluate the mode of cell death, asynchronous KPL-1 cells were exposed to DHA or CDHA at IC_{50} for 72 hours, in DMEM supplemented with 10% FBS. To evaluate cell cycle progression, after serum starvation (incubated with FBS-free medium) for 24 hours synchronous KPL-1 cells were exposed to each test compound at the same

concentration in DMEM supplemented with 10% FBS for 0, 3, 6, or 24 hours. Both asynchronous and synchronous KPL-1 cells were treated as follows. The adhered and floating cells were mixed and washed twice in phosphate-buffered saline (PBS)(-) followed by centrifugation, and fixed in 70% ethanol. Then, the cells were treated with 1 mg/ml RNase, diluted with PBS(-), and stained with 50 µg/ml propidium iodide in PBS(-). Cells were analyzed by FACScan (Becton Dickson, Mountain View, CA, USA) using Cell Quest software. Cell cycle distribution was quantified with Modfit LT software (Verity Software House, Topsham, ME, USA), using a doublet discrimination module to eliminate the possibility of confusing multiples of G₁ cells with ordinary G₂ cells.

Western blotting analysis

KPL-1 cells were examined for expression of p53, p21^{Cip1/Waf1}, cyclin D₁, Bax, and Bcl-2 proteins. KPL-1 cells were exposed to DHA or CDHA for 3, 6 and 24 hours, or for 24, 48 and 72 hours (at the IC₅₀ dose for 72 hours) and compared with unexposed cells. Immunoblotting was performed as previously described [23]. Briefly, cell pellets were homogenized using lysis buffer (50 mmol/l Tris-HCl [pH 6.8], 2% SDS, 5 mmol/l β-mercaptoethanol, 10% glycerol). Cell lysates were clarified by centrifugation at 13,500 g for 40 min. Protein concentrations were measured by Bio-Rad assay (Bio-Rad, Richmond, CA, USA), and 70 µg protein from each sample was mixed with loading buffer, electrophoresed on 15% SDS polyacrylamide gels, and blotted onto nitrocellulose membrane (Hybond-P; Amersham Pharmacia Biotech, Buckinghamshire, UK). The membranes were blocked with 5% dry milk in Tris-buffered saline-Tween for 1 hour at room temperature and probed with anti-p53 (clone DO-7; Dako, Glostrup, Denmark), anti-p21^{Cip1/Waf1} (clone SX-118; BD Biosciences, San Jose, CA, USA), and anti-cyclin D₁ (clone P2D11F11; Novocastra Laboratories, Newcastle upon Tyne, UK) antibodies, and with anti-Bax (BD Biosciences) or anti-Bcl-2 (BD Biosciences) antiserum. Next, the membrane was treated with peroxidase-conjugated goat antimouse or antirabbit IgG antiserum (Envision + system HRP; Dako). Immobilized antigen was detected using ECL plus Western-blotting detection reagents and hyperfilm (Amersham), according to the manufacturer's instructions. Intensity of bands was quantified with the NIH Image1.47 Processing and Analysis program for use with Macintosh computers <http://rsb.info.nih.gov/ni-image/>.

Effect of CDHA on KPL-1 tumor growth in female athymic mice

Female athymic BALB/c-nu/nu mice (age 4 weeks) were purchased from Charles River Japan (Atsugi, Japan). After arrival the mice were randomly assigned to three different dietary groups, with 10 mice in each group and two cages for each group. For basal diet without CDHA, an American

Institute of Nutrition (AIN-76 A) standard reference diet [24] was used. This diet consists of 20% casein, 0.3% DL-methionine, 55% cornstarch, 10% sucrose, 5% cellulose, 5% corn oil, 3.5% AIN-76 mineral mix, 1.0% AIN-76 vitamin mix, and 0.2% choline bitartrate. For diets containing 0.2% or 1.0% CDHA, the appropriate amount of CDHA was added to the basal diet. The diets were prepared at Oriental Yeast (Chiba, Japan) and were stored in sealed plastic bags in the dark at 4°C. During the experimental period the animals were housed in plastic cages with sterilized white pine chips for bedding. The animal room was maintained under specific pathogen-free conditions and was controlled for temperature (22 ± 2°C), light (12-hour cycle), and humidity (60 ± 10%). After the animals had become acclimatization to their respective powdered diets over 2 weeks, the semiconfluent KPL-1 cells growing in DMEM supplemented with 10% FBS at 37°C were trypsinized, and 2 × 10⁷ viable cells/0.25 ml of medium were injected subcutaneously into the area of the right thoracic mammary fat pad using a 26-gauge needle.

The local growing tumor was checked every day before it became visible, and was measured once a week after it became visible. Tumor volume was measured with calipers and calculated using a standard formula [25]: width² × length × 0.5. All mice were killed when the tumors of the basal diet fed group began to exhibit central necrosis (41 days after tumor cell inoculation), and all animals underwent necropsy. At necropsy tumors were weighed and all organs were checked macroscopically. Abnormal organs, locally growing tumors, and axillary lymph nodes were fixed in 10% neutral buffered formalin and processed for hematoxylin-eosin staining. Axillary lymph nodes were evaluated microscopically for metastases.


Data analysis

All results are expressed as means ± standard error. In all *in vitro* experiments, significance of differences was determined using the two-tailed Mann-Whitney U-test for unpaired samples after assuring homogeneity of variance. In *in vivo* experiments, after assurance of homogeneity of variance, analysis was performed using the non-repeated-measures analysis of variance parametric test or the Kruskal-Wallis nonparametric test. If the *P* value of these pretests was below 0.05, then *post hoc* analysis was performed using Fisher's protected least significant difference test to compare body weight, tumor volume, tumor weight, and frequency of metastasis. *P* < 0.05 was considered statistically significant.


Results

Effects of DHA and CDHA *in vitro*

The number of viable KPL-1 cells decreased after treatment with DHA and CDHA (Fig. 1). Dose and time dependent cytotoxicity (reduction in cell number to below the initial

Figure 1

Growth inhibition curves of KPL-1 cells after treatment with docosahexaenoic acid (DHA) or conjugated DHA (CDHA) for 24, 48, and 72 hours. Shown are means \pm standard error for three experiments. The 50% inhibitory concentration (IC_{50}) values indicated are for the 72-hour treatment.


Figure 2

Cell cycle analysis of KPL-1 cells grown in medium alone or treated with 270 $\mu\text{mol/l}$ docosahexaenoic acid (DHA) or 97 $\mu\text{mol/l}$ conjugated DHA (CDHA) 50% inhibitory concentration [IC_{50}] for 72 hours, respectively) for 72 hours. Appearance of sub- G_1 fraction is seen after DHA and CDHA treatment.

plating density) was observed. For 72 hours of treatment, the IC_{50} s of DHA and CDHA were 270 and 97 $\mu\text{mol/l}$, respectively. CDHA was more cytotoxic than DHA toward KPL-1 cells.

Mode of cell death

To determine whether the growth inhibitory activity of DHA and CDHA was related to induction of apoptosis, the effect of both reagents on the cell cycle was analyzed by flow

Figure 3

Cell cycle analysis of synchronous KPL-1 cells grown in medium alone or treated with docosahexaenoic acid (DHA) or conjugated DHA (CDHA) (50% inhibitory concentration [IC₅₀] for 72 hours, respectively) for up to 24 hours. G₀/G₁ arrest is seen after DHA and CDHA treatment. All results were calculated from three independent experiments. **P* < 0.05, ***P* < 0.01, versus controls at the same time point.

cytometry. Representative DNA histograms of asynchronous KPL-1 cells are shown in Fig. 2. At the IC₅₀ for 72 hours, both DHA and CDHA induced appearance of a sub-G₁ fraction, which is characteristic of apoptosis.


Cell cycle progression

Cells in asynchronous cell populations are in different stages of the cell cycle at any given time, making it difficult to interpret changes in cell cycle progression precisely. To examine inhibition of cell growth by DHA or CDHA, synchronous KPL-1 cells were treated with 270 μmol/l DHA or 97 μmol/l CDHA (IC₅₀ concentration for 72 hours). Cell cycle was synchronized by serum starvation for 24 hours followed by refeeding. Cell cycle fraction was recorded after 3, 6, and 24 hours of treatment with each test compound, and was compared with cells incubated in medium alone. Representative DNA histograms for synchronous cells and data from three independent experiments are shown in Fig. 3. Among synchronous cells incubated in medium alone, 71 ± 2% of cells were in G₀/G₁ phase and 19 ± 2% were in S phase. At 3 hours after refeeding, the


percentage of cells in G₀/G₁ decreased to 37 ± 1% and the percentage in S phase increased to 43 ± 5%. At 6 hours the percentage of cells in G₂/M phase increased to 22 ± 0%. In cells treated with DHA or CDHA, cell cycle progression was comparable with that in cells in medium alone until 6 hours after re-feeding. However, after 24 hours of incubation with DHA or CDHA, the percentage of cells in S phase was lower (15 ± 7% and 12 ± 0%, respectively) and the percentage of cells in G₀/G₁ was higher (53 ± 10% and 76 ± 4%, respectively), as compared with cells incubated in medium alone, suggesting G₀/G₁ arrest. After 24 hours of incubation, the percentage of cells in G₂/M phase was high (32 ± 3%) among cells treated with DHA but not among cells treated with CDHA (17 ± 5%), as compared with cells incubated in medium alone (12 ± 1%). DHA may have induced cell arrest in the early stage of G₀/G₁ phase, leading to accumulation of cells in G₂/M phase.

Changes in cell cycle regulators and apoptosis inducers

Cell cycle regulatory proteins, including p53, p21^{Cip1/Waf1}, and cyclin D₁, were examined. Representative Western


Figure 4

Expression of **(a)** p53, p21^{Cip1/Waf1} and cyclin D₁, and **(b)** Bax and Bcl-2 in KPL-1 cells grown in medium alone (control) or treated with docosahexaenoic acid (DHA) or conjugated DHA (CDHA).


Figure 5

Quantification of **(a)** p53, p21^{Cip1/Waf1} and cyclin D₁, and **(b)** Bax and Bcl-2 protein expression in KPL-1 cells treated with docosahexaenoic acid (DHA) or conjugated DHA (CDHA), compared with control (designated 100%). All results were calculated from three independent samples. **P* < 0.05, versus controls.

blotting results are shown in Fig. 4a, and data from three independent experiments using individually prepared lysates are summarized in Fig. 5a. Density of immunoreactive bands in DHA-treated or CDHA-treated samples is expressed as percentage of the density of corresponding bands in control samples, which were designated 100%. In KPL-1 cells, both DHA and CDHA at IC₅₀ for 72 hours increased levels of p53 and p21^{Cip1/Waf1}, and decreased levels of cyclin D₁ at 3, 6 and 24 hours, as compared with untreated control cells. Changes in the apoptosis acceler-

Figure 6

Effect of dietary conjugated docosahexaenoic acid (CDHA) on body weight change in female BALB/c athymic mice before and after KPL-1 inoculation. Values are expressed as mean ± standard error for 10 mice.


Figure 7

Growth of KPL-1 cells injected subcutaneously into the area of the right thoracic mammary fat pad of female BALB/c athymic mice at 6 weeks of age. Values are expressed as mean ± standard error for 10 tumors. CDHA, conjugated docosahexaenoic acid.

ating protein Bax and the apoptosis suppressing protein Bcl-2 were examined 24, 48 and 72 hours after treatment. Although the level of Bax was not altered at these time points, a decrease in Bcl-2 level was observed (Figs 4b and 5b).

Effects of CDHA in vivo

There was no evidence of gross toxicity resulting from the 0.2% or 1.0% CDHA diets. There were no significant differences in body weight change among groups (Fig. 6) and no deaths occurred. However, growth of KPL-1 cells, as evaluated by tumor volume, was always less in CDHA-fed mice than in CDHA-unfed controls (Fig. 7). At the end of

Figure 8

Scattergram showing KPL-1 primary tumor volume and lymph node metastasis for diets containing 0%, 0.2%, or 1.0% conjugated docosa-hexaenoic acid (CDHA).

the study tumor volume was significantly reduced in 1.0% CDHA-treated mice ($855 \pm 88 \text{ mm}^3$) compared with CDHA-unfed controls ($1314 \pm 223 \text{ mm}^3$; $P < 0.05$); the 0.2% CDHA diet ($1193 \pm 138 \text{ mm}^3$) had no significant effect. Although a 26% reduction in tumor weight was observed in 1.0% CDHA treated mice compared with CDHA-unfed controls (1170 ± 158 and $1580 \pm 261 \text{ mg}$, respectively), the difference was not significant; tumor weight was not reduced in 0.2% CDHA treated mice ($1581 \pm 157 \text{ mg}$). Axillary lymph node metastasis was observed in 60% (6/10) of control mice, 50% (5/10) of 0.2% CDHA-treated mice, and 40% (4/10) of 1.0% CDHA-treated mice (i.e. metastasis gradually decreased with increasing amount of ingested CDHA). In each dietary group metastasis tended to correlate with the size of the primary tumor (Fig. 8). Further experiments are needed to determine whether metastasis *per se* is affected by CDHA.

Discussion

DHA inhibited the growth of KPL-1 human breast cancer cells *in vitro*, with an IC_{50} of $270 \mu\text{mol/l}$. In a previous study serum concentration of DHA in rats was $97.3 \mu\text{g/ml}$ ($297 \mu\text{mol/l}$) after 4 weeks of DHA supplementation [26]. Thus, the present IC_{50} for DHA may be relevant to tumor progression *in vivo*. CDHA inhibited KPL-1 cell growth more effectively than did DHA *in vitro*. CDHA isomerized by alkaline treatment exhibited cytotoxicity, with an IC_{50} of $97 \mu\text{mol/l}$, which is 2.8-fold more potent than the parent DHA. The

conjugated fatty acid most widely studied for its anticarcinogenic effects is CLA, a conjugated dienoic acid. In addition, conjugated trienoic fatty acids exhibit cytotoxic effects in cultured human tumor cell lines [27], and conjugated tetraenes exert cytotoxicity on human leukemia cells [28]. In the present study CDHA rich in conjugated pentaene and hexaene was shown to be cytotoxic against KPL-1 human breast cancer cells.

Garden balsam seed oil, which contains conjugated tetraenes, and tung, bitter gourd, pomgranata, catalpa and pot marigold seed oil, which contain high amounts of conjugated trienes, are cytotoxic to tumor cells of mouse and human origin [28,29]. These naturally occurring seed oils each contain one major isomer [30]. In contrast, like CLA formed by partial bacterial hydrogenation of the parent linoleic acid in the rumen of ruminant animals, conjugated fatty acids prepared by alkaline isomerization contain a mixture of complex positional (location of double bonds) and geometric (cis/trans combinations) isomers. Determining which isomer(s) exhibits potent anticarcinogenic action requires further study.

DHA-induced reduction of tumor cell growth is generally attributed to induction of apoptotic cell death [31] and its effects on cell cycle progression [32]. DHA reduces cyclin D₁, E and A associated kinase activity in HT-29 human colon cancer cells. Thus, DHA may exert its negative effect on growth of tumor cells by inhibiting activation and expression of G₁-associated cell cycle regulatory proteins [33]. In the present study, like its parent DHA, CDHA induced apoptosis and affected cell cycle regulatory proteins. Cell cycle analysis exhibited G₁ arrest, which involves increases in p53 and p21^{Cip1/Waf1} and a decrease in G₁ cyclin (cyclin D₁). CDHA induces apoptosis in human colorectal adenocarcinoma cells [21]. In the present study apoptosis was seen in KPL-1 cells; the apoptosis cascade involved downregulation of Bcl-2, whereas Bax expression was unchanged. Thus, the growth inhibitory mechanisms of CDHA involve positive regulation of apoptosis and negative regulation of cell cycle progression.

In the present study, CDHA suppressed growth of human breast cancer cells transplanted into athymic mice. Previous studies indicate that CLA is a powerful anticancer agent in the rat mammary cancer model, with significant effects of CLA obtained at dietary doses of 1.0% and less [34]. Suppression of mammary carcinogenesis in rats can be achieved with a diet containing less than 1.0% conjugated α -linolenic acid (derived from perilla oil) [35]. The dietary doses at which conjugated fatty acids have tumor-suppressing effects is strikingly low compared with n-3 PUFAs, which require a dietary dose of 5–10% to achieve comparable effects [8,19,36]. In the present study the dose of CDHA (0.2–1.0% in the AIN-76A diet) was deter-

mined in accordance with findings of previous studies of conjugated fatty acid. A dietary dose of 1.0% CDHA suppressed KPL-1 cell growth in athymic mice.

Conclusion

CDHA exhibited an inhibitory effect on KPL-1 human breast carcinoma cells in culture, and modulated apoptosis cascades and cell cycle progression. Also, CDHA suppressed KPL-1 cell growth in athymic mice with no side effects. CDHA, which has relatively low toxicity, has potential as a dietary chemopreventive/chemotherapeutic agent against human breast cancer, and possibly in management of other forms of cancer. Determining which positional and geometric isomers are responsible for this anticarcinogenic effect will require further study.

Competing interests

None declared.

Acknowledgements

The authors thank Ms T Akamatsu for her excellent technical assistance in tissue preparation, and Ms Y Yoshida for preparing the manuscript. This study was supported in part by a Health and Labor Science Research Grant for Research on Food and Chemical Safety, from the Ministry of Health, Labor and Welfare, Japan.

References

- Doll R, Peto R: **The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today.** *J Natl Cancer Inst* 1981, **66**:1191-1308.
- Hunter DJ, Spiegelman D, Adami HO, Beeson L, van den Brandt PA, Folsom AR, Fraser GE, Goldbohm RA, Graham S, Howe GR, Kushi LH, Marshall JR, McDermott A, Miller AB, Speizer FE, Wolk A, Yaun S-S, Willett W: **Cohort studies of fat intake and the risk of breast cancer: a pooled analysis.** *N Engl J Med* 1996, **334**:356-361.
- Bartsch H, Nair J, Owen RW: **Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers.** *Carcinogenesis* 1999, **20**:2209-2218.
- Bang HO, Dyerberg J, Hjoorne N: **The composition of food consumed by Greenland Eskimos.** *Acta Med Scand* 1976, **200**:69-73.
- Nobmann ED, Byers T, Lanier AP, Hankin JH, Jackson MY: **The diet of Alaska Native adults: 1987-1988.** *Am J Clin Nutr* 1992, **55**:1024-1032.
- Kaizer L, Boyd NF, Kriukov V, Tritcher D: **Fish consumption and breast cancer risk: an ecological study.** *Nutr Cancer* 1989, **12**:61-68.
- Rose DP, Connolly JM, Coleman M: **Effect of omega-3 fatty acids on the progression of metastasis after the surgical excision of human breast cancer cell solid tumor growing in nude mice.** *Clin Cancer Res* 1996, **2**:1751-1756.
- Senzaki H, Iwamoto S, Ogura E, Kiyozuka Y, Arita S, Kurebayashi J, Takada H, Hioki K, Tsubura A: **Dietary effects of fatty acids on growth and metastasis of KPL-1 human breast cancer cells in vivo and in vitro.** *Anticancer Res* 1998, **18**:1621-1628.
- Hirose M, Masuda A, Ito N, Kamano K, Okuyama H: **Effect of dietary perilla oil, soybean oil and safflower oil on 7,12-dimethylbenzanthracene (DMBA) and 1,2-dimethylhydrazine (DMH)-induced mammary gland and colon carcinogenesis in female SD rats.** *Carcinogenesis* 1990, **11**:731-735.
- Hirose M, Nishikawa A, Shibutani M, Imai T, Shirai T: **Chemoprevention of heterocyclic amine-induced mammary carcinogenesis in rats.** *Environ Mol Mutagen* 2002, **39**:271-278.
- Ha YL, Grimm NK, Pariza MW: **Anticarcinogens from fried ground beef: heat-altered derivatives of linoleic acid.** *Carcinogenesis* 1987, **8**:1881-1887.
- MacDonald HB: **Conjugated linoleic acid and disease prevention: a review of current knowledge.** *J Am Coll Nutr* 2000, Suppl:111S-118S.
- Kelly GS: **Conjugated linoleic acid: a review.** *Altern Med Rev* 2001, **6**:367-382.
- Pariza MW, Park Y, Cook ME: **The biologically active isomers of conjugated linoleic acid.** *Prog Lipid Res* 2001, **40**:283-298.
- Ip C, Chin SF, Scimeca JA, Pariza MW: **Mammary cancer prevention by conjugated dienoic derivative of linoleic acid.** *Cancer Res* 1991, **51**:6118-6124.
- Thompson H, Zhu Z, Banni S, Darcy K, Loftus T, Ip C: **Morphological and biochemical status of mammary gland as influenced by conjugated linoleic acid: implication for a reduction in mammary cancer risk.** *Cancer Res* 1997, **57**:5067-5072.
- Ip C, Banni S, Angioni E, Carta G, McGinly J, Thompson HJ, Barbano D, Bauman D: **Conjugated linoleic acid-enriched butter fat alters mammary gland morphogenesis and reduces cancer risk in rats.** *J Nutr* 1999, **129**:2135-2142.
- O'Shea M, Devery R, Lawless F, Murphy J, Stanton C: **Milk fat conjugated linoleic acid (CLA) inhibits growth of human mammary MCF-7 cancer cells.** *Anticancer Res* 2000, **20**:3591-3601.
- Yuri T, Danbara N, Tsujita-Kyutoku M, Fukunaga K, Takada H, Inoue Y, Hada T, Tsubura A: **Dietary docosahexaenoic acid suppresses N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats more effectively than eicosapentaenoic acid.** *Nutr Cancer* 2003, **45**:211-217.
- Lopez A, Gerwick WH: **Two new icosapentaenoic acids from the temperate red seaweed *Ptilota filicina* J. Agardh.** *Lipids* 1987, **22**:190-194.
- Igarashi M, Miyazawa T: **Do conjugated eicosapentaenoic acid and conjugated docosahexaenoic acid induce apoptosis via lipid peroxidation in cultured human tumor cells?** *Biochem Biophys Res Commun* 2000, **270**:649-656.
- Kurebayashi J, Kurosumi M, Sonoo H: **A new human breast cancer cell line, KPL-1 secretes tumor-associated antigens and grows rapidly in female athymic nude mice.** *Br J Cancer* 1995, **71**:845-853.
- Nakagawa H, Tsuta K, Kiuchi K, Senzaki H, Tanaka K, Hioki K, Tsubura A: **Growth inhibitory effects of diallyl disulfide on human breast cancer cell lines.** *Carcinogenesis* 2001, **22**:891-897.
- Bieri JG, Stoewsand GS, Briggs GM, Phillips RW, Woodard JC, Knapka JJ: **Report of the American Institute of Nutrition ad hoc Committee on Standards for Nutritional Studies.** *J Nutr* 1977, **107**:1340-1348.
- Geran RI, Greenberg NH, McDonald MM, Schumacher AM, Abbott BJ: **Protocol for screening chemical agents and natural products against animal tumors and other biological systems.** *Cancer Chemother Rep* 1972, **3**:1-103.
- Mizota A, Sato E, Taniai M, Adachi-Usami E, Nishikawa M: **Protective effects of dietary docosahexaenoic acid against kainate-induced retinal degeneration in rats.** *Invest Ophthalmol Vis Sci* 2001, **42**:216-221.
- Igarashi M, Miyazawa T: **Newly recognized cytotoxic effect of conjugated trienoic fatty acids on cultured human tumor cells.** *Cancer Lett* 2000, **148**:173-179.
- Cornelius AS, Yerram NR, Kratz DA, Spector AA: **Cytotoxic effect of cis-parinaric acid in cultured malignant cells.** *Cancer Res* 1991, **51**:6025-6030.
- Suzuki R, Noguchi R, Ota T, Abe M, Miyashita K, Kawada T: **Cytotoxic effect of conjugated trienoic fatty acids on mouse tumor and human monocytic leukemia cells.** *Lipids* 2001, **36**:477-482.
- Takagi T, Itabashi Y: **Occurrence of mixtures of geometrical isomers of conjugated octadecatrienoic acids in some seed oils: analysis by open-tubular gas liquid chromatography and high performance liquid chromatography.** *Lipids* 1981, **16**:546-551.
- Connolly JM, Gilhooly EM, Rose DP: **Effects of reduced dietary linoleic acid intake, alone or combined with an algal source of docosahexaenoic acid, on MDA-MB-231 breast cancer cell growth and apoptosis in nude mice.** *Nutr Cancer* 1999, **35**:44-49.

32. Istfan NW, Wan J, Chen ZY: **Fish oil and cell proliferation kinetics in a mammary carcinoma tumor model.** *Adv Exp Med Biol* 1995, **375**:149-156.
33. Chen ZY, Istfan NW: **Docosahexaenoic acid, a major constituent of fish oil diets, prevents activation of cyclin-dependent kinases and S-phase entry by serum stimulation in HT-29 cells.** *Prostaglandins Leukot Essent Fatty Acids* 2001, **64**:67-73.
34. Ip C, Scimeca JA, Thompson HJ: **Conjugated linoleic acid. A powerful anticarcinogen from animal fat sources.** *Cancer* 1994, **74**:1050-1054.
35. Futakuchi M, Cheng JL, Hirose M, Kimoto N, Cho Y-M, Iwata T, Kasai M, Tokudome S, Shirai T: **Inhibition of conjugated fatty acids derived from safflower or perilla oil of induction and development of mammary tumors in rats induced by 2-amino-1-methyl-6-phenylimidazo (4,5-b) pyridine (PhIP).** *Cancer Lett* 2002, **178**:131-139.
36. Takata T, Minoura T, Takada H, Sakaguchi M, Yamamura M, Hioki K, Yamamoto M: **Specific inhibitory effect of dietary eicosapentaenoic acid on N-nitroso-N-methylurea-induced mammary carcinogenesis in female Sprague-Dawley rats.** *Carcinogenesis* 1990, **11**:2015-2019.